Your browser is no longer supported. Please, upgrade your browser.
ATRA Atara Biotherapeutics, Inc. daily Stock Chart
Atara Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-5.47 Insider Own1.30% Shs Outstand61.21M Perf Week-12.48%
Market Cap1.01B Forward P/E- EPS next Y-4.11 Insider Trans-3.33% Shs Float43.24M Perf Month51.34%
Income-298.20M PEG- EPS next Q-1.21 Inst Own90.50% Short Float31.36% Perf Quarter60.69%
Sales- P/S- EPS this Y-7.70% Inst Trans-0.25% Short Ratio7.81 Perf Half Y-18.10%
Book/sh4.13 P/B3.28 EPS next Y11.40% ROA-93.10% Target Price- Perf Year-26.11%
Cash/sh2.88 P/C4.70 EPS next 5Y- ROE-109.00% 52W Range4.52 - 19.36 Perf YTD-17.85%
Dividend- P/FCF- EPS past 5Y-0.20% ROI- 52W High-29.55% Beta2.33
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low201.77% ATR0.95
Employees409 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)54.78 Volatility6.85% 7.67%
OptionableYes Debt/Eq0.00 EPS Q/Q16.40% Profit Margin- Rel Volume0.64 Prev Close13.53
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume1.74M Price13.64
Recom2.00 SMA202.77% SMA5017.17% SMA20010.58% Volume1,101,911 Change0.81%
Jun-30-20Initiated Evercore ISI Outperform
Jun-15-20Initiated H.C. Wainwright Buy $25
Apr-23-20Upgrade Citigroup Neutral → Buy $14
Nov-08-19Downgrade JP Morgan Overweight → Neutral $43 → $22
Sep-27-19Downgrade Goldman Neutral → Sell $14 → $9
Sep-16-19Downgrade Jefferies Buy → Hold $32 → $15
Jun-04-19Upgrade Citigroup Sell → Neutral $23 → $24
May-30-19Initiated ROTH Capital Buy
May-23-19Initiated Stifel Buy
Jan-23-19Initiated Mizuho Buy
Apr-10-18Initiated JP Morgan Overweight $56
Mar-16-18Initiated Guggenheim Neutral
Mar-05-18Reiterated Jefferies Buy $30 → $46
Feb-28-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-15-18Downgrade Citigroup Neutral → Sell
Jan-03-18Upgrade Citigroup Sell → Neutral
Oct-06-17Resumed Goldman Neutral
Jun-22-17Resumed Jefferies Buy $30
Oct-24-16Resumed Jefferies Buy
Sep-15-16Downgrade Goldman Neutral → Sell
Jul-01-20 11:28AM  
Jun-30-20 10:19AM  
Jun-24-20 04:34PM  
Jun-23-20 09:48PM  
Jun-17-20 08:47AM  
Jun-15-20 09:57AM  
Jun-05-20 04:15PM  
Jun-04-20 04:01PM  
May-27-20 01:16AM  
May-26-20 04:05PM  
May-19-20 08:30AM  
May-18-20 04:30PM  
May-15-20 09:38AM  
May-14-20 04:05PM  
May-13-20 09:21AM  
May-11-20 04:01PM  
May-08-20 04:12AM  
May-07-20 02:00PM  
May-06-20 04:01PM  
Apr-30-20 04:01PM  
Apr-22-20 08:30PM  
Apr-14-20 04:41PM  
Apr-02-20 08:33AM  
Mar-26-20 10:19AM  
Feb-28-20 07:04AM  
Feb-27-20 07:35AM  
Feb-21-20 04:00PM  
Feb-20-20 04:00PM  
Feb-19-20 04:00PM  
Feb-05-20 08:30AM  
Jan-12-20 02:00PM  
Dec-24-19 10:10AM  
Dec-18-19 07:59AM  
Dec-11-19 11:04PM  
Dec-10-19 12:22PM  
Dec-09-19 10:00AM  
Nov-26-19 04:00PM  
Nov-12-19 09:00AM  
Nov-08-19 05:02AM  
Nov-07-19 07:30AM  
Nov-06-19 09:01AM  
Oct-30-19 04:05PM  
Oct-28-19 12:39PM  
Oct-25-19 06:11PM  
Sep-27-19 11:54AM  
Sep-26-19 07:37AM  
Sep-23-19 01:16PM  
Sep-13-19 07:40AM  
Sep-12-19 06:21PM  
Sep-10-19 01:58PM  
Sep-09-19 08:00AM  
Aug-28-19 04:05PM  
Aug-16-19 08:35AM  
Aug-08-19 02:43PM  
Aug-05-19 02:08PM  
Aug-01-19 04:00PM  
Jul-18-19 11:52PM  
Jul-16-19 07:00AM  
Jul-09-19 01:58PM  
Jul-01-19 09:25AM  
Jun-29-19 07:00AM  
Jun-25-19 04:05PM  
Jun-23-19 03:52PM  
Jun-05-19 04:30PM  
Jun-04-19 09:36AM  
Jun-03-19 11:00AM  
Jun-01-19 09:00AM  
May-30-19 05:38PM  
May-28-19 05:00PM  
May-24-19 05:24AM  
May-15-19 05:05PM  
May-09-19 03:25PM  
May-07-19 04:41PM  
May-02-19 12:42PM  
Apr-23-19 08:44AM  
Apr-01-19 04:10PM  
Mar-31-19 11:00AM  
Mar-08-19 01:55PM  
Mar-07-19 09:00AM  
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Touchon PascalPresident and CEOJun 25Sale12.9212,135156,784264,844Jun 26 04:18 PM
Koppikar UtpalChief Financial OfficerJun 09Sale10.183,92439,946135,026Jun 10 04:05 PM
Newell JoeChief Operations OfficerMay 18Sale11.221,60317,986123,881May 20 06:11 PM
Koppikar UtpalChief Financial OfficerMay 18Sale11.221,42816,022137,375May 20 06:11 PM
Touchon PascalPresident and CEOMay 18Sale11.223,19535,848276,979May 20 06:10 PM
Newell JoeChief Operations OfficerApr 06Sale7.946575,217125,484Apr 07 04:21 PM
Newell JoeChief Operations OfficerMar 27Sale9.172,74025,126126,141Mar 30 04:05 PM
Koppikar UtpalChief Financial OfficerMar 27Sale9.171,82716,754137,330Mar 30 04:06 PM
Newell JoeChief Tech. Operations OfficerFeb 06Sale14.214,11758,50353,881Feb 10 07:48 PM
Koppikar UtpalChief Financial OfficerFeb 06Sale14.211,78125,30872,282Feb 10 07:47 PM
Newell JoeChief Tech. Operations OfficerSep 27Sale13.513,50047,28557,998Sep 30 04:25 PM